Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622) (DETECT)
A Pivotal, Prospective, Multi-centre, Randomised Controlled, 6-month Blinded Investigation Followed by a 6-month Open-label Phase Evaluating the Efficacy of a Dexamethasone Eluting Slim Straight Electrode (CI622D) in the Reduction of Impedance as Compared to a Standard Slim Straight Electrode (CI622) in a Newly Implanted Adult Population With Post-linguistic, Bilateral, Moderately Severe to Profound Sensorineural Hearing Loss.
Sponsor: Avania
Listed as NCT06424262, this NA trial focuses on Hearing Loss, Bilateral and Hearing Loss, Bilateral Sensorineural and remains ongoing. Sponsored by Avania, it has been updated 9 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting NA
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting NA
-
Sep 2025 — Jan 2026 [monthly]
Active Not Recruiting NA
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — May 2025 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Avania
- Cochlear
- QbD Clinical
For direct contact, visit the study record on ClinicalTrials.gov .